Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates

Annovis Bio Inc. (NYSE: ANVS) has announced a live webcast scheduled for June 24, 2025, at 4:30 PM EDT, where President and CEO Maria Maccecchini, Ph.D., will share updates on the company's pivotal Phase 3 trial for early Alzheimer’s disease and recent FDA feedback regarding its Parkinson’s disease program. This event underscores Annovis Bio's commitment to advancing treatments for neurodegenerative diseases, which affect millions worldwide. The webcast will feature a presentation followed by a Q&A session, offering stakeholders, including shareholders and patients, insights into the company's progress and future directions.

The significance of this webcast lies in the potential impact of Annovis Bio's therapies on the treatment of Alzheimer’s and Parkinson’s diseases. By targeting multiple neurotoxic proteins, the company aims to restore brain function and improve patients' quality of life. The updates on the Phase 3 trial and FDA feedback are critical milestones that could pave the way for new treatment options, addressing a significant unmet medical need in neurodegenerative diseases.

Annovis Bio's efforts represent a beacon of hope for patients and families affected by Alzheimer’s and Parkinson’s diseases. The upcoming webcast is an opportunity for the medical community and investors to gain a deeper understanding of the company's innovative approach to tackling these challenging conditions. The implications of Annovis Bio's work extend beyond the immediate patient population, potentially influencing the broader field of neurodegenerative disease research and treatment strategies.